These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35436670)

  • 41. Pramlintide (Amylin).
    Barlocco D
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1575-81. PubMed ID: 11763160
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modeling energy intake and body weight effects of a long-acting amylin analogue.
    Brings A; Borghardt JM; Skarbaliene J; Baader-Pagler T; Deryabina MA; Rist W; Scheuerer S
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):215-233. PubMed ID: 29170989
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.
    Orskov L; Nyholm B; Yde Hove K; Gravholt CH; Møller N; Schmitz O
    Diabet Med; 1999 Oct; 16(10):867-74. PubMed ID: 10547215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.
    Chapman I; Parker B; Doran S; Feinle-Bisset C; Wishart J; Lush CW; Chen K; Lacerte C; Burns C; McKay R; Weyer C; Horowitz M
    Obesity (Silver Spring); 2007 May; 15(5):1179-86. PubMed ID: 17495194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight.
    Gydesen S; Andreassen KV; Hjuler ST; Christensen JM; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2016 May; 310(10):E821-7. PubMed ID: 26908506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus.
    Vella A; Lee JS; Camilleri M; Szarka LA; Burton DD; Zinsmeister AR; Rizza RA; Klein PD
    Neurogastroenterol Motil; 2002 Apr; 14(2):123-31. PubMed ID: 11975712
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.
    Ravussin E; Smith SR; Mitchell JA; Shringarpure R; Shan K; Maier H; Koda JE; Weyer C
    Obesity (Silver Spring); 2009 Sep; 17(9):1736-43. PubMed ID: 19521351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic pramlintide decreases feeding via a reduction in meal size in male rats.
    Kern KA; DiBrog AM; Kaur K; Przybysz JT; Mietlicki-Baase EG
    Peptides; 2024 Jun; 176():171197. PubMed ID: 38493922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pramlintide for the treatment of diabetes mellitus.
    Kleppinger EL; Vivian EM
    Ann Pharmacother; 2003; 37(7-8):1082-9. PubMed ID: 12841822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimizing diabetes treatment using an amylin analogue.
    Edelman SV
    Diabetes Educ; 2008; 34 Suppl 1():4S-10S. PubMed ID: 18268000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development.
    Chan JL; Roth JD; Weyer C
    J Investig Med; 2009 Oct; 57(7):777-83. PubMed ID: 20029268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pramlintide in the treatment of diabetes mellitus.
    Edelman S; Maier H; Wilhelm K
    BioDrugs; 2008; 22(6):375-86. PubMed ID: 18998755
    [TBL] [Abstract][Full Text] [Related]  

  • 55. KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats.
    Andreassen KV; Larsen AT; Sonne N; Mohamed KE; Karsdal MA; Henriksen K
    Mol Metab; 2021 Nov; 53():101282. PubMed ID: 34214708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide.
    Kolterman OG
    Diabet Med; 1997 Jun; 14 Suppl 2():S35-8. PubMed ID: 9212328
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts.
    Mousa YM; Abdallah IM; Hwang M; Martin DR; Kaddoumi A
    Sci Rep; 2020 Feb; 10(1):3751. PubMed ID: 32111883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy.
    Larsen AT; Sonne N; Andreassen KV; Gehring K; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2019 Jul; 370(1):35-43. PubMed ID: 31028106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
    Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
    Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Physico-chemical properties of co-formulated fast-acting insulin with pramlintide.
    da Silva DC; Lima LMTR
    Int J Pharm; 2018 Aug; 547(1-2):621-629. PubMed ID: 29928940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.